Serum Urate During Acute Gout

被引:94
作者
Schlesinger, Naomi [1 ]
Norquist, Josephine M. [2 ]
Watson, Douglas J. [2 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Rheumatol, New Brunswick, NJ 08903 USA
[2] Merck Res Labs, Dept Epidemiol, N Wales, PA USA
关键词
GOUT; ACUTE GOUT; SERUM URATE; ARTHRITIS; INDOMETHACIN; SOLUBILITY; ETORICOXIB; TRIAL;
D O I
10.3899/jrheum.080938
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective. To study the frequency of normal serum urate (SU) levels during acute gout in the largest studies of acute gout treatment to date. Methods. Data collected from 2 randomized controlled clinical trials assessing the efficacy of etoricoxib or indomethacin for 7 days in acute gout were used to assess SU levels during acute gouty attacks. Efficacy was similar with both agents, so both groups were combined for analysis. Results. A total of 339 patients were enrolled in the 2 studies; 94% were male; mean age was 50.5 years. At baseline, 14% of patients had a "true" nornial SU (<= 6 mg/dl) and 32% had SU <= 8 mg/dl during acute gout. Baseline mean SU was 7.1 versus 8.5 mg/dl (p < 0.001) in those taking allopurinol versus nonusers. Patients taking Chronic allopurinol were more likely to have lower SU at baseline compared to those not taking chronic allopurinol (p < 0.001) during the acute attack. Conclusion. A normal SU level at presentation does not exclude an acute gouty attack. In the largest studies of acute gout to date, attacks still occurred despite SU levels being below 6.8 mg/dl, the saturation level for urate. This may be attributed to persistence of tophi and an increased body uric acid pool. Additional Studies are needed to determine the correlation between SU and the body uric acid pool as well as the relationship to timing of changes during acute gout. (First Release April 15 2009: J Rheumatol 2009;36:1287-9; doi: 10.3899/jrheum.080938)
引用
收藏
页码:1287 / 1289
页数:3
相关论文
共 10 条
[1]
FACTORS AFFECTING URATE SOLUBILITY INVITRO [J].
KIPPEN, I ;
KLINENBERG, JR ;
WEINBERGER, A ;
WILCOX, WR .
ANNALS OF THE RHEUMATIC DISEASES, 1974, 33 (04) :313-317
[2]
INFLUENCE OF TEMPERATURE ON SOLUBILITY OF MONOSODIUM URATE [J].
LOEB, JN .
ARTHRITIS AND RHEUMATISM, 1972, 15 (02) :189-+
[3]
LOGAN JA, 1995, BR J RHEUMATOL S2, V34, P40
[4]
GOUT WITHOUT HYPERURICEMIA [J].
MCCARTY, DJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (04) :302-303
[5]
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout -: A randomized controlled trial [J].
Rubin, BR ;
Burton, R ;
Navarra, S ;
Antigua, J ;
Londoño, J ;
Pryhuber, KG ;
Lund, M ;
Chen, EL ;
Najarian, DK ;
Petruschke, RA ;
Ozturk, ZE ;
Geba, GP .
ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :598-606
[6]
Schlesinger N, 1997, J RHEUMATOL, V24, P2265
[7]
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis [J].
Schumacher, HR ;
Boice, JA ;
Daikh, DI ;
Mukhopadhyay, S ;
Malmstrom, K ;
Ng, J ;
Tate, GA ;
Molina, J .
BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7352) :1488-1492
[8]
ABC OF RHEUMATOLOGY - GOUT, HYPERURICEMIA, AND CRYSTAL ARTHRITIS [J].
SNAITH, ML .
BRITISH MEDICAL JOURNAL, 1995, 310 (6978) :521-524
[9]
Urano W, 2002, J RHEUMATOL, V29, P1950
[10]
Weinberger Abraham, 1995, Current Opinion in Rheumatology, V7, P359, DOI 10.1097/00002281-199507000-00017